<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39342891</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2120</ISSN><JournalIssue CitedMedium="Internet"><Volume>153</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Bioorganic chemistry</Title><ISOAbbreviation>Bioorg Chem</ISOAbbreviation></Journal><ArticleTitle>Simplified scalable synthesis of a water-soluble toll-like receptor 2 agonistic lipopeptide adjuvant for use with protein-based viral vaccines.</ArticleTitle><Pagination><StartPage>107835</StartPage><MedlinePgn>107835</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioorg.2024.107835</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0045-2068(24)00740-5</ELocationID><Abstract><AbstractText>Toll-like receptors (TLRs) form a key bridge between the innate and adaptive immune systems. The lipopeptide based TLR2 agonists such as Pam<sub>2</sub>CSK<sub>4</sub> are promising vaccine adjuvants but drawbacks include its surfactant like nature and cumbersome synthesis. Although the TLR2 activity of Pam<sub>2</sub>CS-OMe is commensurate with Pam<sub>2</sub>CSK<sub>4</sub>, its water solubility is much less, rendering it ineffective for clinical use. In the present investigation, we designed a synthesis pathway for a novel water-soluble TLR2-active analogue, Pam<sub>2</sub>CS-DMAPA (13), which enhanced the immunogenicity of recombinant SARS-CoV2 and hepatitis B antigens in mice. Co-formulation of compound 13 with 2 % aluminium hydroxide gel led to a further significant improvement in vaccine immunogenicity. This synthetically simpler compound 13 was water soluble and equally potent to Pam<sub>2</sub>CSK<sub>4</sub> adjuvant, but was superior in terms of manufacturing simplicity and scalability. This makes compound 13 a promising TLR2 targeted adjuvant for further development.</AbstractText><CopyrightInformation>Copyright © 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brar</LastName><ForeName>Deshkanwar S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh 160014, India; National Interdisciplinary Centre of Vaccine Immunotherapeutics and Antimicrobials, Panjab University, Chandigarh 160014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Arshpreet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh 160014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Madhuri T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Mehr Chand Mahajan DAV College for Women, Chandigarh 160036, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda-Okubo</LastName><ForeName>Yoshikazu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Vaxine Pty Ltd, 11 Walkley Avenue, Warradale, South Australia 5046, Australia; Australian Respiratory and Sleep Medicine Institute, Bedford Park, South Australia 5042, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrovsky</LastName><ForeName>Nikolai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Vaxine Pty Ltd, 11 Walkley Avenue, Warradale, South Australia 5046, Australia; Australian Respiratory and Sleep Medicine Institute, Bedford Park, South Australia 5042, Australia; National Interdisciplinary Centre of Vaccine Immunotherapeutics and Antimicrobials, Panjab University, Chandigarh 160014, India. Electronic address: nikolai.petrovsky@vaxine.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salunke</LastName><ForeName>Deepak B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh 160014, India; National Interdisciplinary Centre of Vaccine Immunotherapeutics and Antimicrobials, Panjab University, Chandigarh 160014, India. Electronic address: salunke@pu.ac.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bioorg Chem</MedlineTA><NlmUniqueID>1303703</NlmUniqueID><ISSNLinking>0045-2068</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adjuvant</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Lipopeptide</Keyword><Keyword MajorTopicYN="N">Pam(2)CSK(4)</Keyword><Keyword MajorTopicYN="N">TLR2</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Deepak B. Salunke reports financial support and administrative support were provided by Panjab University. Prof. Nikolai Petrovsky reports financial support was provided by National Institute of Allergy and Infectious Diseases. Prof. Nikolai Petrovsky and Dr. Deepak B. Salunke reports financial support was provided by Global Connections Fund. Dr. Deepak B. Salunke reports financial support was provided by Ministry of Human Resources, Government of India. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39342891</ArticleId><ArticleId IdType="doi">10.1016/j.bioorg.2024.107835</ArticleId><ArticleId IdType="pii">S0045-2068(24)00740-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle>